Dr. Schwartz is the Deputy Director and Executive Vice President for Research and Academic Affairs at the Karmanos Cancer Institute and a Professor in the Department of Oncology at Wayne State University School of Medicine.
In 2009, she served as Interim President and CEO of the Karmanos Cancer Institute. Dr. Schwartz has been continuously funded by the National Cancer Institute for 20 years, has over 115 publications, and serves as a reviewer for numerous journals and NIH grants, including a recent term on Subcommittee A, the parent committee for Comprehensive Cancer Center Support Grants. Her lung cancer studies have focused on familial aggregation of lung cancer, producing the first estimates of lung cancer risk to relatives in African Americans, evaluation of candidate genes in smoking and estrogen metabolism pathways, and gene discovery using admixture mapping in African Americans. Most recently she has published in the area of inflammation and lung cancer risk, showing 1) increased risk of lung cancer with a history of chronic obstructive lung diseases collectively, and emphysema and chronic bronchitis separately, 2) decreased risk associated with NSAID use, 3) variation in risk and survival associated with SNPs in inflammatory genes, and 4) decreased survival associated with COX-2 but not with EGFR expression in lung tumors in both white and African Americans. Dr. Schwartz has also conducted gene expression studies in prostate cancer using custom array panels for a study of racial disparities in prostate cancer aggressiveness. She is an active participant in two lung cancer consortiums, the Genetic Epidemiology of Lung Cancer Consortium (GELCC) and the International Lung Cancer Consortium (ILCCO), and a pancreatic cancer gene discovery consortium (PacGene).